%0 Journal Article
%T The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization
%A Ansgar Br¨¹ning
%A Martina Rahmeh
%A Andrea Gingelmaier
%A Klaus Friese
%J Molecular Cancer
%D 2010
%I BioMed Central
%R 10.1186/1476-4598-9-19
%X By combining in vitro and ex vivo studies, the effect of nelfinavir on leukemia cells and non-malignant, bone marrow-derived tissue cells was analyzed.At a concentration of 9 ¦Ìg/ml, nelfinavir induced death of 90% of HL60, IM9, and Jurkat cells. At the same concentration and treatment conditions, less than 10% of aspirated human bone marrow cells showed nelfinavir-induced cell damage. Nelfinavir-induced death of leukemia cells was accompanied by activation of caspases 3, 7, and 8. Despite caspase activation, the upregulation of the anti-apoptotic bcl-2 family member protein mcl-1 that resulted from nelfinavir treatment stabilized the mitochondrial membrane potential, resulting in primarily mitochondria-independent cell death. Pharmacological downregulation of mcl-1 expression by treatment with sorafenib (2 ¦Ìg/ml) significantly enhanced nelfinavir-induced apoptosis even at lower nelfinavir concentrations (5 ¦Ìg/ml), but did not have additional detrimental effects on non-malignant bone marrow cells.The ability of nelfinavir to induce apoptosis in leukemia cells as a single agent in a mitochondria-independent manner might suggest it could be used as a second or third line of treatment for leukemia patients for whom standard mitochondria-directed treatment strategies have failed. Combination treatment with nelfinavir and sorafenib might further enhance the efficacy of nelfinavir even on chemo-resistant leukemia cells.Blood cancer cells are highly sensitive to cytostatic drugs but, depending on the cancer type, often become resistant after initial therapy, necessitating second and even third line treatment therapies. Thus, there is a need for additional new anti-cancer drugs that induce specific cell death pathways in leukemia cells. It has recently been shown that the HIV protease inhibitor nelfinavir (Viracept£¿) can induce cell death in a variety of human cancer types [1,2], and clinical studies with nelfinavir are currently proposed or underway [3-6]. Nelfinavir appear
%U http://www.molecular-cancer.com/content/9/1/19